Additionally, by incorporating a hydrophobic region into plinabulin’s structure, we developed a novel FLT3-ITD-selective inhibitor 5-3, which may serve as a drug candidate for the treatment of FLT3-ITD-positive AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.